Amarin Reports Strong Q4 2025 Performance as VASCEPA/VAZKEPA Franchise Positioned to Benefit from Emerging Triglyceride Therapies
Key Insights
Amarin achieved significant operational improvements in Q4 2025, narrowing operating losses by 88% to $6.3 million while reducing operating expenses by 31% through strategic restructuring initiatives.
The company returned to positive cash flow ahead of schedule and ended 2025 with $302.6 million in cash and no debt, positioning it for sustained profitability in 2026.
VASCEPA/VAZKEPA is uniquely positioned to benefit from new ApoC-III (search) therapies through payor-driven step therapy programs, similar to how ezetimibe experienced 15% annual growth following PCSK9 inhibitor launches.
Amarin Corporation reported strong fourth quarter 2025 financial results, demonstrating significant operational improvements while positioning its VASCEPA/VAZKEPA franchise to capitalize on emerging therapies for elevated triglycerides. The company narrowed its operating loss by 88% to $6.3 million compared to $52.5 million in Q4 2024, while total operating expenses decreased 31% to $29.5 million.
Financial Performance Drives Positive Outlook
The Dublin and Bridgewater-based pharmaceutical company achieved several key financial milestones in Q4 2025. Total net revenue reached $49.2 million, with the company returning to positive cash flow ahead of schedule. Amarin ended 2025 with $302.6 million in cash and investments with no debt, representing an $8.4 million year-over-year increase.
"Our performance in the fourth quarter and full year of 2025 confirmed both the initial impact and long-term potential of our strategic initiatives and re-imagined operating model," said Aaron Berg, President and Chief Executive Officer of Amarin. "We have entered 2026 from an improved position of market, operational, and financial strength."
The company's restructuring initiatives yielded $31 million of the expected $70 million in cost savings, with selling, general and administrative expenses decreasing $16.9 million or 46% compared to the prior year period. Peter Fishman, Amarin's Chief Financial Officer, noted that the company has positioned itself "to generate positive cash flow for the full year ahead."
Strategic Positioning in Evolving Treatment Landscape
Amarin highlighted how recent innovations in triglyceride therapies, particularly new ApoC-III (search)-targeted injectables, are likely to expand utilization of existing proven options like VASCEPA/VAZKEPA through payor-driven step therapy programs. The company drew parallels to the 2015 launch of PCSK9 inhibitors, which drove sustained growth for ezetimibe averaging approximately 15% annually over eight years despite a previously declining market.
"Innovative therapeutics coupled with related FDA breakthrough therapy designations, underscore the renewed focus on recognizing and treating the risks in patients with elevated triglycerides," Berg stated. "VASCEPA/VAZKEPA has also been approved for cardiovascular risk reduction (CVRR) in over 50 countries and recognized for CVRR by more than 70 global medical societies."
U.S. payors have already implemented step-therapy programs for new ApoC-III (search) injectables within currently approved familial chylomicronemia syndrome indications, which could result in increased utilization of existing drugs such as VASCEPA as a payor-preferred, first-line therapy prior to access to newer, higher cost ApoC-III therapies.
Proven Clinical Efficacy and Global Expansion
VASCEPA/VAZKEPA has demonstrated robust clinical evidence, with the landmark REDUCE-IT cardiovascular outcomes trial showing a 25% decrease in cardiovascular events when used as an adjunct to statin therapy in patients with elevated triglyceride levels. The study included 8,179 patients and was published in 2018.
In the Company's pivotal MARINE study in patients with triglycerides between 500 and 2,000 mg/dL, approximately 50% of those treated orally with VASCEPA 4g/day achieved triglyceride levels below 500 mg/dL at week 12. Importantly, the reduction in triglyceride levels observed with VASCEPA was not associated with elevations in low-density lipoprotein cholesterol levels relative to placebo, unlike other triglyceride-lowering agents.
The drug has been prescribed more than 25 million times globally and is now commercially available in more than 20 countries. In 2025, Amarin secured an exclusive long-term license and supply agreement with Recordati S.p.A. (search) to commercialize VAZKEPA across 59 countries, focused on Europe where patent protection extends until 2039.
Market Position and Future Outlook
VASCEPA is FDA approved as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride levels ≥ 150 mg/dL and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease. The drug is also approved as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
Unlike other triglyceride-lowering agents such as fibrates, niacin and mixed omega-3 products, which have failed in prior cardiovascular outcomes trials, and unlike newer triglyceride-lowering agents targeting ApoC-III (search) protein, which have not yet been studied for cardiovascular outcomes, VASCEPA has already demonstrated robust efficacy in reducing cardiovascular events when added on top of statin therapy.
The company's commercialization model includes a direct sales approach in the U.S. and an indirect distribution strategy internationally through established partners with geographic expertise, covering close to 100 markets worldwide. With its proven safety profile, broad reimbursement coverage, and established clinical evidence, VASCEPA/VAZKEPA is positioned to benefit from the expanding focus on triglyceride management as new therapies enter the market.